Which high-growth cloud play is a better buy at current prices?
If you're new to biotech investing, these are three companies you need to know.
New sales guidance for Gilead Sciences suggests that the company's struggles could continue to disappoint investors this year.
Which clinical-stage biotech stock wins in a head-to-head match-up between Agenus and Alnylam?
Data from a competitor gives investors hope that the company's drug will have a larger potential market.
Following Takeda's multibillion-dollar acquisition of cancer drugmaker Ariad Pharmaceuticals, Array Biopharma, Seattle Genetics, and Exelixis could be the next to be bought.
Why AbbVie, Amgen, and Baxter beat Gilead Sciences on some key criteria for investors.
Gilead Sciences' capital return program is doing little to bulk up the share price, and that suggests it's time for the company to get serious about acquisitions.
Looking for cheap biotech stocks you can buy now? These three may be bargains.
Drug development is a tough business. Here's a closer look at seven of the biggest biotech flops of the year.